• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Novartis and the Biotrial scandal in France

anonymous

Guest
Go figure: NIBR's Eric Legangneux is a consultant to Biotrial and best buddy with Patat. Until now noone took notice here that NIBR - with Eric's help - had contracted Biotrial surprisingly often. Check the numbers! Any kickbacks involved? Which role did Eric play in their deadly dosing game?
 

<



Go figure: NIBR's Eric Legangneux is a consultant to Biotrial and best buddy with Patat. Until now noone took notice here that NIBR - with Eric's help - had contracted Biotrial surprisingly often. Check the numbers! Any kickbacks involved? Which role did Eric play in their deadly dosing game?

it sounds interesting.
tell me more.
 








he is involved in the BIA 10-2474 project if you know what this means

another example of the imprudent pharma company synthesizing a treatment for chronic pain, when there is already natural plant substance that, when administered in appropriate dose and mechanism of delivery, does same thing and doesn't leave you dead from an overdose. and hey, you can grow it yourself! now calm down boys and girls, we don't want those pill-popping patients to take direct management of their therapy from seed to stomach. we add real value! and pollute the environment!
 




another example of the imprudent pharma company synthesizing a treatment for chronic pain, when there is already natural plant substance that, when administered in appropriate dose and mechanism of delivery, does same thing and doesn't leave you dead from an overdose. and hey, you can grow it yourself! now calm down boys and girls, we don't want those pill-popping patients to take direct management of their therapy from seed to stomach. we add real value! and pollute the environment!

And if people were more active rather than living relatively sedentary lifestyles compared to those of their parents' and grandparents' generations, another pillar of the Big Pharma (and NVS) business model would collapse.